Roger Finch.pdf

More documents

Recommendations

Info

Key technology needs tosupport these strategic goals New medicines Vaccines to control drug resistantinfections as well as diseases Electronic surveillance of infections andresistance trendsto deliver safe Electronic monitoring of and drug effective usagecare!’ Electronic prescribing support Rapid/near patient diagnostics‘The right ‘tools’
Future scenario ‐ antibacterials‘Blockbuster’ drugs are now essentially historicalTargeted treatments are increasingly requiredThe h focus should ldbe on quality and not on quantity –novelty rather than ‘me‐too’More robust definitions of endpoints including duration oftreatment are key to clinical use and patient safety andgreater efficiency in drug developmentBUT – a repertoire of new agents is needed@ $1billion + 10 years to develop eachBSAC –The Urgent Need
Page 1: BSAC: Celebrating 40 years of achie
Page 4 and 5: Decline in the licensing of new ant
Page 6 and 7: Development of new classesof antiba
Page 8 and 9: Streptococcus pneumoniae infections
Page 10 and 11: What pathogens/diseasesrequire new
Page 12 and 13: Strategic control of antibioticresi
Page 16 and 17: The EducationalChallengeUK NHS Staf
Page 18 and 19: Antimicrobial Stewardship Programme
Page 20 and 21: The advantages of better andfaster
Page 22 and 23: POC/Rapid diagnostics and drugDisad
Page 24 and 25: The Way Forward Pharma & biotech -

Roger Finch.pdf

Create successful ePaper yourself

Delete template?

Save as template?